Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.66 | N/A | +16.81% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.66 | N/A | +16.81% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future prospects. They emphasized the importance of innovation and adapting to market changes.
Management highlighted ongoing efforts to enhance product pipeline.
They acknowledged challenges in the current market environment.
Focus remains on long-term growth despite short-term pressures.
Pfizer's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.34% likely due to the lack of revenue details and guidance, which left investors uncertain about future performance. The cautious tone from management may also have contributed to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Feb 2, 2026